SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Isotechnika
An SI Board Since August 2001
Posts SubjectMarks Bans Symbol
285 8 0 ISA
Emcee:  schzammm Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
85Pfizer (evidently) has a drug under development that looks like a potential compIcebrg-6/18/2003
84Isotechnika/Roche's ISA247 comparable to cyclosporine for kidney transplant Icebrg-6/11/2003
83Icebrg, thanks for your many informative posts. ISA is knocking on the door of aschzammm-6/9/2003
82Maas BiolAB Granted pan-European Cyclosporin Neuroprotection Patent Monday June Icebrg-6/9/2003
81ICOS Regains Full Rights to LFA-1 Program Friday June 6, 7:01 am ET Moves ForwarIcebrg-6/6/2003
80Isotechnika Releases Final Results of Phase IIa Kidney Transplant Trial at AmeriIcebrg-6/4/2003
79Drug swap could keep kidneys running The arrival of a new generation of drug thIcebrg-6/3/2003
78Icebrg, The side effects mentioned in the abstract for the renal trial results wteevee-6/2/2003
77>>why proceed with further trials?>> Neoral over time destroys the Icebrg-6/2/2003
76If ISAtx247 has a similar incidence of adverse events to Neoral despite 3-fold teevee-6/2/2003
75[1215] PHASE 2, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY OF ISA247 AND NEORAL IIcebrg-6/2/2003
74Transplant Pioneer Rejects Approach He Helped Create By MICHAEL WALDHOLZ Staff Icebrg-6/2/2003
73Biomaven, <i>Of course fast track status is not a magic bullet - some drugteevee-6/1/2003
72mTOR inhibitor Isotechnica announced a couple of days ago, that they are startiIcebrg-5/30/2003
71>>The Friedman Billings Ramsey Technology and Growth investor conference wIcebrg-5/29/2003
70The Friedman Billings Ramsey Technology and Growth investor conference webcast cteevee-5/29/2003
69Isotechnika to participate in Friedman Billings Ramsey Technology and Growth invteevee-5/29/2003
68Peter >> Note that 247, because it is an immunosuppressant, is always goiIcebrg-5/26/2003
67>>Oral Pimecrolimus This appears to concentrate in the skin - so good forBiomaven-5/26/2003
66Oral Pimecrolimus Thanks Peter. That appears to be something relatively similarIcebrg-5/26/2003
65One notable competitor from that table is what may turn out to be the most signiBiomaven-5/26/2003
64>> Plenty of competition in the psoriasis market>> Yes, there is a Icebrg-5/26/2003
63Plenty of competition in the psoriasis market psoriasis.orgschzammm-5/26/2003
62Comment from ISA letter to shareholders from the 1st quarter results: sedar.comteevee-5/25/2003
61<b>Immunosuppressive Therapies in Organ Transplantation from Organ TransplIcebrg-5/24/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News